Revance Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Revance Therapeutics

09/05/2023 23:05

* Revance Therapeutics Inc  RVNC.OQ  reported a quarterly
adjusted
loss of 74 cents​​ per share for the quarter ended in March. The
mean expectation of twelve analysts for the quarter was for a
loss of 70 cents per share.
    * Revenue rose 95.3% to $49.33 million from a year ago;
analysts
expected $46.10 million. 
    * Revance Therapeutics Inc's reported EPS for the quarter
was a
loss of 74 cents​.
    * The mean earnings estimate of analysts had risen by
about 3.8%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * Revance Therapeutics Inc shares had risen by 13.6% this
quarter and gained 98.3% so far this year.
    * The company reported a quarterly loss of $59.79 million.
    * Wall Street's median 12-month price target for Revance
Therapeutics Inc is $38.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
9 at 10:05 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.70          -0.74          Missed
 Dec. 31 2022      -0.95          -0.95          Met
 Sep. 30 2022      -0.89          -1.17          Missed
 Jun. 30 2022      -0.86          -0.88          Missed